Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators.
about
Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Atrial fibrillation: review of current treatment strategies2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.What should we expect from the next generation of antiarrhythmic drugs?Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department.Antiarrhythmic drugs for atrial fibrillation.Pharmacological management of atrial fibrillation: an update.Pharmacological management of atrial fibrillation: one, none, one hundred thousand.Treating critical supraventricular and ventricular arrhythmias.Drug-induced QT interval prolongation: mechanisms and clinical managementTreatment of atrial flutter.Antiarrhythmic drugs: from mechanisms to clinical practice.Proarrhythmia, a serious complication of antiarrhythmic drugs.Atrial fibrillation: the most common arrhythmiaPure class III antiarrhythmic drugs: focus on dofetilide.Pharmacotherapy of atrial fibrillation.What niche will newer class III antiarrhythmic drugs occupy?Mechanisms of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias.Drug-induced long QT syndromeIbutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation.Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter.Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillationSpecial problems with antiarrhythmic drugs in the elderly: safety, tolerability, and efficacy.Emergency management of atrial fibrillationAdvances in the acute pharmacologic management of cardiac arrhythmias.Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalolSuperiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.Pharmacologic management of arrhythmias in patients with congenital heart disease.Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation.Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility.Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.Role of electrophysiological study and ablation in the management of recurrent atrial flutter associated with haemodynamic compromise in a critically ill patient.Phase synchrony reveals organization in human atrial fibrillationAtrial fibrillation: choosing an antiarrhythmic drug.Do we need pharmacological therapy for atrial fibrillation in the ablation era?Ibutilide for treatment of atrial fibrillation in the emergency departmentProarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients.
P2860
Q26747032-1F2FC89E-0EB5-4A86-9FD6-00CAF0909E9FQ27341873-CC6394C8-8AAB-4E84-AC94-9254A7B39479Q28073181-0431C992-413A-4EE4-BA3D-BFDB20B39B2BQ30653045-EB64D6D2-087E-436E-8D5A-552069FE5468Q33544548-ADDCCFCA-F2F2-4067-8953-3FAB4968C99DQ33544553-9C74F998-81E0-4987-9E12-EE7372F31D4BQ33589789-E39BB71D-B336-4F48-BEC5-07C328EC536FQ33821199-93D95DF8-2827-4FFA-A583-ED1F0BF2BE95Q33845159-7EAE7EE7-8017-415C-91B9-4D8ABC50A2E3Q33902193-F3102D0C-53FB-476B-AECD-18363752F07CQ33909242-1496EA38-5DB9-43B0-8CF3-1FE3F8D92FFFQ33949538-FC19279F-443B-4A11-8E95-DFB31F07BFA3Q33977959-A485F1B4-B024-4B2D-B11D-C666F19085ACQ34012641-E441C248-DD78-4463-9B0E-3F17B00A15EDQ34027347-8F9AAE0A-00A3-45A9-9F58-6590B1BD475FQ34091039-292967CF-CC55-4547-A5F8-4E95058C2F3CQ34126027-52FED7ED-9737-4B6D-B9F9-D67C4D38C988Q34182375-5FD52E61-462D-4C68-B338-3BFFA0F823BFQ34282152-40BC8BE6-0953-4131-93F4-353E8131C269Q34308117-6D3BC101-29D9-4920-8E45-B2BB2002A374Q34358104-D40341AE-80F9-49DE-9416-BB264F3E4A7FQ34422636-EA500265-6486-4B8F-B9B1-D03AD81EBBCEQ34491925-F535EA2E-29B0-4D8F-A085-DC1C277E7E75Q34523170-EA1F2826-1CE4-4708-8DC4-246A562F30EDQ34989738-E267D905-26B6-4DFF-A0C0-D241F8DF0E31Q35168643-11C4ABF6-7DEC-4EF2-9605-7A83BF9343E2Q35198974-EC8252ED-63E1-4195-AF87-5256BF2AF2A3Q35211438-EEC5D9E4-1EB7-4ABE-8500-221BC689507DQ35368049-76696AF0-0337-41ED-8590-0F1DFFC2B01BQ35631363-1B253EFE-36B7-46E0-A988-6058AFD1395DQ35771784-9818C1F8-DE6C-4F5A-96ED-008A0146DCC4Q35814463-A6DE5BB6-2075-47E9-808B-F3F43132BEE2Q35892164-B5639EEB-6298-46F4-A087-535FD36FFD64Q35892167-4503D5D6-ADFF-48AE-B7C3-06C4A09DAC51Q36093387-D7D19B00-8DD3-446A-A5A3-3FBC9F66B09CQ36422609-D8EAB75F-0806-42F6-A4F5-F2E2A1E0468BQ36587004-B54A730C-78A4-4F24-A2C0-20BCDDFCDB1AQ36752772-B984D010-66F1-4C88-99BD-9ABD22E325F7Q36929148-59FE2504-5A92-4B66-B22A-84850BB41747Q36970774-E8C51AFA-476F-4C32-8325-587B8F45BDF0
P2860
Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators.
description
1996 nî lūn-bûn
@nan
1996 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Efficacy and safety of repeate ...... peat Dose Study Investigators.
@ast
Efficacy and safety of repeate ...... peat Dose Study Investigators.
@en
Efficacy and safety of repeate ...... peat Dose Study Investigators.
@nl
type
label
Efficacy and safety of repeate ...... peat Dose Study Investigators.
@ast
Efficacy and safety of repeate ...... peat Dose Study Investigators.
@en
Efficacy and safety of repeate ...... peat Dose Study Investigators.
@nl
prefLabel
Efficacy and safety of repeate ...... peat Dose Study Investigators.
@ast
Efficacy and safety of repeate ...... peat Dose Study Investigators.
@en
Efficacy and safety of repeate ...... peat Dose Study Investigators.
@nl
P2093
P356
P1433
P1476
Efficacy and safety of repeate ...... peat Dose Study Investigators.
@en
P2093
Ellenbogen KA
Stambler BS
VanderLugt JT
Wakefield LK
P304
P356
10.1161/01.CIR.94.7.1613
P407
P577
1996-10-01T00:00:00Z